Education on Increased ICP Reduces Nursing ‘Headache’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 11
Volume 11
Issue 11

WASHINGTON-Managing the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.

WASHINGTON—Managing the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.

When turnover in the nursing staff left a neuro-oncology unit devoid of nurses knowledgeable in basic neurological assessment and experienced at identifying the signs and symptoms of increased intracranial pressure, an effective and convenient teaching method became imperative. A nurse-designed self-study module met the need, Ms. Baumgartner and her colleague Susan Hummel, RN, MN, CNS, reported at the Oncology Nursing Society (abstract 83) Congress.

Based on guidelines from the Brain Trauma Foundation, the module included a pretest, written instructional material, a post-test, and an evaluation form. Four experienced oncology nurses who were nonetheless new to neuro-oncology used the module in a pilot study. At pretest, the nurses correctly answered an average of only 60% of questions. After studying with the module, they averaged 90% correct. Their evaluations of the written material suggested revisions were needed to explain more specifically the pathophysiology of increased intracranial pressure. Once the module is approved for continuing education credit, it will be made available to other nurses at the facility, she said. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.